Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-322 add-on versus pioglitazone dose escalation in type 2 diabetes inadequately controlled on metformin plus pioglitazone
2006-006025-73Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alogliptin, pioglitazone and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoints: Change from baseline in HbA1c at Week 26 and Change from baseline in HbA1c at Week 52. Started Feb 2007; status: completed.
02
Drugs
alogliptinpioglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006025-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006025-73.